TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33171516

Group type: EXPERIMENTAL
Intervention: 17G needle
Number of subjects: 43

Group type: COMPARATOR
Intervention: 20‐17G needle
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cohorts with degenerative oocytes
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cohorts with no degenerative oocytes
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cohorts without degenerative oocytes
Number of subjects: 43
Study: 32058357

Group type: EXPERIMENTAL
Intervention: Velocity-based (VB) training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rating of Perceived Exertion (RPE) training
Number of subjects: 20
Study: 33764378

Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation (positive end-expiratory pressure, 10-12 cm H2O; pressure support, 10-12 cm H2O) for at least 48 hours
Number of subjects: 109

Group type: COMPARATOR
Intervention: High-flow nasal oxygen (60 L/min)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation
Number of subjects: 109

Group type: COMPARATOR
Intervention: High-flow nasal oxygen
Number of subjects: 109
Study: 32222900

Group type: EXPERIMENTAL
Intervention: Software-generated apnea-hypopnea index (sAHI) derived from photoplethysmogram data (PPG)
Number of subjects: 0
Study: 36274534

Group type: EXPERIMENTAL
Intervention: Allium hirtifolium bulbs (500 mg twice daily for 6 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 32631080

Group type: EXPERIMENTAL
Intervention: Mobile phone app intervention
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (no mobile app)
Number of subjects: 191
Study: 35725644

Group type: EXPERIMENTAL
Intervention: ADM + self-guided i-CBT
Number of subjects: 3360

Group type: EXPERIMENTAL
Intervention: ADM + guided i-CBT
Number of subjects: 3360

Group type: COMPARATOR
Intervention: ADM only
Number of subjects: 3360
Study: 32677876

Group type: EXPERIMENTAL
Intervention: Low dose (1 × 10^7 cells)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Medium dose (2 × 10^7 cells)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High dose (5 × 10^7 cells)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 22
Study: 35394359

Group type: EXPERIMENTAL
Intervention: Feedback group (tailored feedback: visual diagram, verbal instructions, video examples)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no tailored feedback)
Number of subjects: 23
Study: 33751917

Group type: EXPERIMENTAL
Intervention: Endoscopic injection of Dextranomer/Hyaluronic Acid (Dx/HA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lich-Gregoir open technique of ureteral reimplantation
Number of subjects: 60
Study: 34984626

Group type: EXPERIMENTAL
Intervention: Phacoemulsification and intraocular lens (IOL) implantation
Number of subjects: 78
Study: 34033222

Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 32151567

Group type: EXPERIMENTAL
Intervention: Anodal-(L)dlPFC/cathodal-(R)vmPFC tDCS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reversed polarity tDCS
Number of subjects: 15
Study: 35279176

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (educational meeting, ongoing training, workshops, implementation teams, Plan-Do-Study-Act cycles)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Single implementation strategy (one educational meeting)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Number of subjects: 700

Group type: COMPARATOR
Intervention: Single implementation strategy
Number of subjects: 700
Study: 32063251

Group type: EXPERIMENTAL
Intervention: Auditory brainstem response (ABR) profiling test for schizophrenia (SZ)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Auditory brainstem response (ABR) profiling test for ADHD
Number of subjects: 16
Study: 35965313

Group type: EXPERIMENTAL
Intervention: Electronic portfolio
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Online discussion forum
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 34115851

Group type: EXPERIMENTAL
Intervention: ZTL-101 (sublingual cannabinoid extract)
Number of subjects: 24
Study: 35903418

Group type: EXPERIMENTAL
Intervention: Module intervention (flipchart format)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 120
Study: 34257355

Group type: EXPERIMENTAL
Intervention: Previous statin use
Number of subjects: 0
Study: 35606221

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 scales
Number of subjects: 0
Study: 32191569

Group type: EXPERIMENTAL
Intervention: Personalized psychosocial intervention (eight 1-hour weekly sessions plus one booster)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 173
Study: 616497272

Group type: EXPERIMENTAL
Intervention: Intravenous etomidate alone (group E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous propofol alone (group P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etomidate combined with propofol (group EP)
Number of subjects: 60
Study: 35965066

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 159

Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 159
Study: 34142409

Group type: EXPERIMENTAL
Intervention: Magnetic marker localization (MaMaLoc)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wire-guided localization (WGL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 36279931

Group type: EXPERIMENTAL
Intervention: Multifaceted, site-specific intervention focused on evidence-based care for patients with T2DM
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 42
Study: 34424991

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SBU; etch‐and‐rinse mode)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Scotchbond Universal (SBU; self-etch mode)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: OptiBond XTR (OPT; etch‐and‐rinse mode)
Number of subjects: 80

Group type: COMPARATOR
Intervention: OptiBond XTR (OPT; self-etch mode)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond Quick (CL; etch‐and‐rinse mode)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clearfil Universal Bond Quick (CL; self-etch mode)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adhese Universal (ADH; etch‐and‐rinse mode)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Adhese Universal (ADH; self-etch mode)
Number of subjects: 80
Study: 32512364

Group type: EXPERIMENTAL
Intervention: Fatty Fish (FF, n=20)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Camelina sativa oil (CSO, n=18)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Lean Fish (LF, n=21)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 79
Study: 35624551

Group type: EXPERIMENTAL
Intervention: Recovery group
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Dilatation group
Number of subjects: 125

Group type: COMPARATOR
Intervention: Reflux group
Number of subjects: 125
Study: 33763982

Group type: EXPERIMENTAL
Intervention: 3.2 MHz ultrasound toothbrush
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4.8 MHz ultrasound toothbrush
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1.6 MHz ultrasound toothbrush
Number of subjects: 50
Study: 32766514

Group type: COMPARATOR
Intervention: 2% Lidocaine with 1:80,000 epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% Bupivacaine with 1:200,000 epinephrine
Number of subjects: 60
Study: 33645416

Group type: EXPERIMENTAL
Intervention: Mindfulness-based mobile app
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: In-person mindfulness-based program (IMBP)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study: 33540157

Group type: EXPERIMENTAL
Intervention: Inclusion group (exclusive breastfeeding mothers)
Number of subjects: 88
Study: 33170461

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 274

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 274
Study: 32492577

Group type: EXPERIMENTAL
Intervention: Food Insecure Households
Number of subjects: 503
Study: 35850533

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise, 20-60 min per session, three times per week for twelve weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Exercise education (control group)
Number of subjects: 73
Study: 34118700

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal (CR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sitting quietly (Control)
Number of subjects: 50
Study: 32445735

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 158
Study: 34587794

Group type: EXPERIMENTAL
Intervention: Deep learning model for predicting final infarct volume
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Deep learning model for predicting individual infarct growth rates
Number of subjects: 228
Study: 33159976

Group type: EXPERIMENTAL
Intervention: ACT-539313 200 mg b.i.d.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 32405550

Group type: EXPERIMENTAL
Intervention: Silicone gel plus herbal extract gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 36315949

Group type: EXPERIMENTAL
Intervention: Ticagrelor‐aspirin
Number of subjects: 6378

Group type: COMPARATOR
Intervention: Clopidogrel‐aspirin
Number of subjects: 6378
Study: 32475444

Group type: EXPERIMENTAL
Intervention: Basal diet + 200 mg/kg chitosan (CS200)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 320
Study: 32557838

Group type: EXPERIMENTAL
Intervention: Motor skills At Playtime (MAP) intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (outdoor free play)
Number of subjects: 46
Study: 35291272

Group type: EXPERIMENTAL
Intervention: Resistant starch 2 (RS2) at doses of 10, 15, and 20 g/d
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sugarcane bagasse at doses of 5, 10, and 15 g/d
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of RS2 and sugarcane bagasse at doses of 20, 25, and 30 g/d
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RS2 ≤ 20 g/d
Number of subjects: 11
Study: 32485759

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) for up to 30 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 40
Study: 34133809

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) during painful dental procedures requiring local anesthesia
Number of subjects: 54

Group type: COMPARATOR
Intervention: Treatment as usual (without VR) during painful dental procedures requiring local anesthesia
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) during non-painful dental procedures
Number of subjects: 54

Group type: COMPARATOR
Intervention: Treatment as usual (without VR) during non-painful dental procedures
Number of subjects: 54
Study: 32542352

Group type: EXPERIMENTAL
Intervention: Guided imagery Intervention Condition (IC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Active behavioral Control Condition (CC)
Number of subjects: 105
Study: 35775872

Group type: EXPERIMENTAL
Intervention: Dysport + Profhilo gel
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dysport
Number of subjects: 19
Study: 33610251

Group type: EXPERIMENTAL
Intervention: Ceftriaxone, cefoxitin, clindamycin, and imipenem
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nim genes
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: cfiA gene
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ermF gene
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: cepA gene
Number of subjects: 62
Study: 32732105

Group type: EXPERIMENTAL
Intervention: 3 mg dinoprostone vaginally
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo vaginally
Number of subjects: 160
Study: 35442180

Group type: EXPERIMENTAL
Intervention: Good CPAP adherence (⩾4 h/night)
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI >40 events/h)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Usual care/poor CPAP adherence
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: OSA (AHI ⩾15 events/h)
Number of subjects: 1803
Study: 33742678

Group type: EXPERIMENTAL
Intervention: Mobilization (to sit in a chair) and standardized breathing exercises (n = 73)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Mobilization (to sit in a chair) only (n = 76)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control (n = 65)
Number of subjects: 214
Study: 32415472

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a prescribed dose of 36.25 Gy in 5 fractions, twice a week
Number of subjects: 28
Study: 33236702

Group type: EXPERIMENTAL
Intervention: HiFive program (6-week handwashing campaign targeting social and emotional motivators)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 196
Study: 34543665

Group type: EXPERIMENTAL
Intervention: Reboxetine plus oxybutynin (Reb‐Oxy)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 32772733

Group type: EXPERIMENTAL
Intervention: Two measles vaccinations (at inclusion and at 9 months of age)
Number of subjects: 237

Group type: COMPARATOR
Intervention: One measles vaccination (at 9 months of age)
Number of subjects: 237
Study: 36377601

Group type: EXPERIMENTAL
Intervention: ixazomib+cyclophosphamide+dexamethasone (ICd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ixazomib+dexamethasone (Id)
Number of subjects: 0
Study: 34304028

Group type: EXPERIMENTAL
Intervention: 360° video VRET incorporating stimuli of audiences (360°Audience), n = 17
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 360° video VRET incorporating stimuli of empty rooms (360°Empty), n = 16
Number of subjects: 51

Group type: COMPARATOR
Intervention: No treatment control, n = 18
Number of subjects: 51
Study: 33139834

Group type: EXPERIMENTAL
Intervention: Downhill running (DR) for 30 minutes at 70% vVO2peak
Number of subjects: 27

Group type: COMPARATOR
Intervention: Level running (LR) for 60 minutes at 70% vVO2peak
Number of subjects: 27
Study: 34380963

Group type: EXPERIMENTAL
Intervention: Solution-Focused Therapy (SFT)
Number of subjects: 124
Study: 34454099

Group type: EXPERIMENTAL
Intervention: Unadjusted analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusted analysis
Number of subjects: 0
Study: 34635989

Group type: EXPERIMENTAL
Intervention: Vilaprisan 1 mg single dose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vilaprisan 5 mg single dose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vilaprisan 15 mg single dose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vilaprisan 1 mg/day for 28 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vilaprisan 5 mg/day for 28 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (single dosing)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (multiple dosing)
Number of subjects: 48
Study: 34270830

Group type: EXPERIMENTAL
Intervention: Isometric leg extension exercise breaks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Walking breaks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no breaks)
Number of subjects: 17
Study: 32997710

Group type: EXPERIMENTAL
Intervention: Two-way text messaging (2wT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 2
Study: 35343844

Group type: EXPERIMENTAL
Intervention: Medication identification device (intervention unit)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medication administration (control unit)
Number of subjects: 70
Study: 33446053

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs)
Number of subjects: 25
Study: 32376491

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 761

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 761
Study: 36151961

Group type: EXPERIMENTAL
Intervention: Combination of transcervical Foley catheter and sublingual misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sublingual misoprostol alone
Number of subjects: 0
Study: 33576037

Group type: EXPERIMENTAL
Intervention: Personal amplifier (PA; Williams Sound Pocketalker 2.0)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no personal amplifier)
Number of subjects: 133
Study: 36202740

Group type: EXPERIMENTAL
Intervention: MND-2119 2 g/day
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: MND-2119 4 g/day
Number of subjects: 122
Study: 34431233

Group type: EXPERIMENTAL
Intervention: Modified Very Low-Energy Diet (VLED)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard Dietary Intervention (SDI)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Composite of adverse pregnancy outcomes
Number of subjects: 164
Study: 32423584

Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg on day 1 followed by 100 mg on days 2-10)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Remdesivir (for patients with symptom duration of 10 days or less)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 237
Study: 36395177

Group type: EXPERIMENTAL
Intervention: COVID-19 papers from highly-ranked institutions
Number of subjects: 78085

Group type: COMPARATOR
Intervention: COVID-19 papers from less reputed institutions
Number of subjects: 78085

Group type: EXPERIMENTAL
Intervention: Single-blind review procedure
Number of subjects: 78085

Group type: COMPARATOR
Intervention: Double-blind review procedure
Number of subjects: 78085

Group type: EXPERIMENTAL
Intervention: COVID-19 papers first authored by women
Number of subjects: 78085

Group type: COMPARATOR
Intervention: COVID-19 papers first authored by men
Number of subjects: 78085
Study: 34463700

Group type: EXPERIMENTAL
Intervention: Lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal (n = 202)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Standard care with conventional low tidal volume ventilation (n = 210)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal
Number of subjects: 412

Group type: COMPARATOR
Intervention: Standard care with conventional low tidal volume ventilation
Number of subjects: 412
Study: 34516959

Group type: EXPERIMENTAL
Intervention: Transitional, tailored, progressive rehabilitation intervention
Number of subjects: 349

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 349
Study: 34521260

Group type: EXPERIMENTAL
Intervention: Atogepant 10 mg
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg
Number of subjects: 873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Atogepant (all doses)
Number of subjects: 873
Study: 33514681

Group type: EXPERIMENTAL
Intervention: Self-collected vaginal swabs
Number of subjects: 12
Study: 33625476

Group type: EXPERIMENTAL
Intervention: Semaglutide, 2.4 mg
Number of subjects: 611

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study: 32608001

Group type: EXPERIMENTAL
Intervention: Selenomethionine (SM) at 0.4 mg/kg diet (SM2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Selenomethionine (SM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sodium selenite (SS) at 0.2 mg/kg diet (SS1)
Number of subjects: 120
Study: 34581859

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound (AUS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Abdominal X-ray (AXR)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Urgent surgery
Number of subjects: 86
Study: 33231130

Group type: EXPERIMENTAL
Intervention: Substance use prevention intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally centered strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based recruitment methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up survey strategies
Number of subjects: 0
Study: 35658604

Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 53

Group type: COMPARATOR
Intervention: Dabrafenib + Trametinib
Number of subjects: 53
Study: 33514408

Group type: EXPERIMENTAL
Intervention: EMDR + active-MtCS
Number of subjects: 45

Group type: COMPARATOR
Intervention: EMDR + sham-MtCS
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waiting List
Number of subjects: 45
Study: 36060658

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 120
Study: 32342848

Group type: EXPERIMENTAL
Intervention: DPIV+AS03B (0-1 month regimen)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: DPIV+AS03B (0-1-6 month regimen)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: DPIV+AS03B (0-3 month regimen)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: DPIV+AS03B
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 36054562

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 400/100 mg plus opicapone 50 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Levodopa/carbidopa 500/125 mg without opicapone
Number of subjects: 24
Study: 33518452

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 2 atm absolute for 2 hours × 20 sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subjects who developed CAS or required stenting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subjects who developed ACR
Number of subjects: 20
Study: 35106809

Group type: EXPERIMENTAL
Intervention: Nebulised unfractionated heparin (UFH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care or placebo (depending on the study design)
Number of subjects: 0